Rapid Enrollment and Dosing of First Patients in PRECISE-AD Trial Underscores the Unmet Need for Better Treatment Options for ...

Hirayama disease is a rare neurological disorder primarily affecting young males. This condition poses diagnostic challenges ...

Rapid Enrollment and Dosing of First Patients in PRECISE-AD Trial Underscores the Unmet Need for Better Treatment Options for Alzheimer's Disease PRECISE-AD Six Month Interim Results Expected in 1H ...

Learn more about whether Corcept Therapeutics Incorporated or Novartis AG is a better investment based on AAII's A+ Investor ...

A woman who was going through a divorce and had her symptoms mistook for stress went on to be diagnosed with motor neurone ...

Medicinova, the company developing ibudilast, is also testing it for amyotrophic lateral sclerosis and drug dependence ... the impact of ibudilast on brain atrophy, or shrinkage, was much ...

Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to targeting cancer and autoimmune ...

A research group led by Gian Gaetano Tartaglia, Principal Investigator at the Italian Institute of Technology (IIT), ...

New research reveals that lower proportions of specific sleep stages are associated with reduced brain volume in regions ...

Astellas has shored up the competitive profile of Izervay as a treatment for eye disorder geographic atrophy (GA), getting FDA approval for an extended treatment duration. The US regulator turned ...

Astellas has suffered another major setback with geographic atrophy (GA) treatment Izervay, this time in the US. The company has received a complete response letter (CRL) from the FDA for a ...

The U.S. Food and Drug Administration approved treatment for 11 patients with the rare familial ALS caused by mutations in ...